▲
STOCKUPSIDE.IO
Analyst Price Target Intelligence
← Full Rankings
← Back to rankings
Ranked #3417 by analyst upside · 2026-09-27
TEVA
Teva Pharmaceutical Industries Limited
Healthcare · Market Cap $46B · P/E 65.3x
ANALYST PRICE TARGET
+12.3%
implied upside to consensus target
Current Price $39.19
Consensus Target $44.0
Bull Target $50.0
Bear Target $40.0
Analysts Covering 5
ANALYST CONSENSUS - BUY
Strong Buy
2
Buy
2
Hold
0
Sell
1
52-Week Low $18.47
52-Week High $40.79
YTD Return +26.6%
FUNDAMENTALS
Market Cap $46B
P/E Ratio (TTM) 65.3x
Forward P/E 12.9x
EPS (TTM) $0.60
PEG Ratio 0.71
Dividend Yield N/A
Revenue (TTM) $17.3B
Profit Margin 4.1%
52-WEEK RANGE
52-Week Low $18.47
52-Week High $40.79
Current Price $39.19
Bear Target $40.0
Bull Target $50.0
● Now $39.19 ● Target $44.0
TRADING DATA
Avg Volume 5.3M
YTD Return +26.6%
Analyst Count 5
Consensus Buy
Upside to Target +12.3%
Last Updated 2026-09-27

ANALYST SUMMARY

Teva Pharmaceutical Industries Limited (TEVA) is currently trading at $39.19 with a Wall Street consensus price target of $44.0, implying potential upside of 12.3% over the next 12 months. 5 analysts currently cover TEVA, with a consensus rating of Buy - 80% of analysts rate the stock a Buy or Strong Buy. The most bullish analyst has a price target of $50.0, while the most cautious has a target of $40.0.

TEVA operates in the Healthcare sector with a market capitalisation of $46B. The stock is up 26.6% year-to-date and is currently trading near the upper end of its 52-week range of $18.47 – $40.79.

SIMILAR STOCKS

Other Healthcare stocks with comparable size and valuation.

RECENT ANALYST CALLS

Upgrade/downgrade history for TEVA, with each firm's 90-day track record across all stocks we track. See full firm rankings →

Oppenheimer ● Initiated
Outperform 2026-09-23 14% win rate (7 calls)
Leerink Partners ● Initiated
Outperform 2026-09-09 29% win rate (7 calls)
UBS - Reiterated
Buy → Buy 2026-09-04 33% win rate (6 calls)
Barclays - Reiterated
Overweight → Overweight 2026-08-12 Building track record
Piper Sandler - Reiterated
Overweight → Overweight 2026-07-28 14% win rate (7 calls)
Barclays - Reiterated
Overweight → Overweight 2026-05-06 Building track record
JP Morgan - Reiterated
Overweight → Overweight 2026-04-30 43% win rate (7 calls)
UBS - Reiterated
Buy → Buy 2026-04-30 33% win rate (6 calls)
HISTORICAL SNAPSHOT

Point-in-time data from StockUpside's daily snapshots. Tracks price, analyst target, upside %, consensus, and analyst count.

Loading…
ANALYST CONVICTION SCORE
61
out of 100
Coverage depth
14/30
Consensus clarity
25/30
Vote unanimity
20/25
Rating stability
2/15

Measures analyst agreement, not fundamental quality. A high score means analysts broadly agree on this call - not that the stock will go up.

See 4,000+ stocks ranked by analyst upside

StockUpside.io tracks analyst consensus price targets across thousands of US-listed stocks, updated every day. The full ranked list is available with a Pro subscription.

View Full Rankings →